Catalog No.
FHD38530
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22, RFB4, RFB 4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20273
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
RFB-4
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331
ST6GAL1 promotes IBD B cell recruitment to the inflamed colon in a CD22-dependent mechanism., PMID:40491026
Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243
Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin., PMID:40435412
Optimal Structural Designs of Trispecific Antibodies to Enhance Therapeutic Efficacy in Solid Tumors and Hematological Malignancies., PMID:40402462
The evolving therapeutic revolution in adult acute lymphoblastic leukemia., PMID:40323723
Management of Adult Acute Lymphoblastic Leukemia: A Review., PMID:40310617
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression., PMID:40306957
Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia., PMID:40181350
[Construction of a camel-derived natural phage nanobody display library and screening of anti-CD22 nanobodies]., PMID:40145457
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia., PMID:40120068
Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series., PMID:40085546
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies., PMID:40057826
ABO-A antibody induction in mice is T cell-dependent, estrogen-independent, and modulated by CD22., PMID:40057198
Tumor-specific cytosol-penetrating antibodies for antigen- and TME-dependent intracellular cargo delivery., PMID:39895690
Effect of high-fat diet on IgA+ cells and BAFF/APRIL in small intestinal villous lamina propria of mice., PMID:39842230
Head-to-Head Comparison of Aptamer- and Antibody-Based Proteomic Platforms in Human Cerebrospinal Fluid Samples from a Real-World Memory Clinic Cohort., PMID:39796148
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review., PMID:39778191
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen., PMID:39694704
Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia., PMID:39648271
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes., PMID:39611241
The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus., PMID:39511302
Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia., PMID:39449299
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia., PMID:39418626
Development and Characterization of A Novel SpyTagged Modular Nanobody as A Detection Platform for CD22-Positive Cells., PMID:39380479
Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance., PMID:39374535
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia., PMID:39236292
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development]., PMID:39191681
Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy., PMID:39148480
Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL)., PMID:39102166
Neu5Gc-mediated high-affinity interaction is dispensable for CD22 cis-ligands to regulate B cell signaling., PMID:39098526
Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report., PMID:39078014
Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases., PMID:38945375
Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia., PMID:38832425
A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery., PMID:38817250
Leukocytospermia and/or Bacteriospermia: Impact on Male Infertility., PMID:38792382
Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair., PMID:38785163
Inotuzumab Ozogamicin: First Pediatric Approval., PMID:38780741
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions., PMID:38734670
Single-cell BCR and transcriptome analysis reveals peripheral immune signatures in patients with thyroid-associated ophthalmopathy., PMID:38728262
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial., PMID:38722664
B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis., PMID:38711503
Oncotherapy resistance explained by Darwinian and Lamarckian models., PMID:38618954
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts., PMID:38610966
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22., PMID:38596311
ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression., PMID:38573563
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL., PMID:38551807
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma., PMID:38550613
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma., PMID:38519055
Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia-A Podcast., PMID:38457052
For research use only. Not for human or drug use.
